2023
Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia
2014
Hand transplants and the mandate for tolerance
Koulmanda M, Pomahac B, Fan Z, Murphy G, Strom T. Hand transplants and the mandate for tolerance. Current Opinion In Organ Transplantation 2014, Publish Ahead of Print: &na;. PMID: 25373855, PMCID: PMC4352932, DOI: 10.1097/mot.0000000000000138.Peer-Reviewed Original ResearchConceptsHand transplantationIL-2Hand transplantLow-dose IL-2IL-2-based therapyBalance of immunityDrug-free toleranceRegulatory T cellsUse of immunosuppressionRecent clinical trialsLife-long immunosuppressionInduction of toleranceNonhuman primate modelShort-term treatmentDrug minimizationPosttransplant periodInflammatory processClinical trialsPrimate modelT cellsPreclinical demonstrationComposite allograftsAdverse inflammationTransplantationTransplant